Watching for answer
$Oncolytics Biotech(ONCY.US$ Oncolytics Biotech Reports Submission Of A Type C Meeting Request To FDA
Benzinga· 3 mins ago
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a transformative year for Oncolytics and our stakeholders."
Benzinga· 3 mins ago
This meeting aims to discuss the company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). "We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a transformative year for Oncolytics and our stakeholders."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
